IL6 inhibitor plus belumosudil for stubborn cGVHD
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests a combination of two drugs for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with belumosudil alone. The first drug, tocilizumab, targets inflammation, and the second, belumosudil, helps regulate the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic GVHD and are currently on belumosudil, but it hasn't worked well enough after at least 3 months.
- Your other chronic GVHD medicines have been at the same dose for at least 2 weeks before starting the study.
- You can do most daily activities on your own (Karnofsky score of 60 or higher).
- You weigh at least 63 kilograms (about 139 pounds).
- You are not currently taking ibrutinib or ruxolitinib (or have stopped them for at least a week).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two medications (belumosudil and ruxolitinib) together for chronic graft-versus-host disease (cGvHD)—a condition where transplanted immune cells attack your body—that did not improve with steroid treatment alone. The trial aims to help patients whose disease is resistant to standard steroids.
This trial tests whether injecting special immune cells (Treg cells) from your transplant donor, along with a protein called IL-2, can help control chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. It is for people who have had a stem cell transplant and still have moderate to severe cGVHD.
This trial tests an experimental drug called Iguratimod for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It aims to see if the drug can safely control cGVHD symptoms when other treatments haven't worked well enough.
This study tests a treatment called anti-CD25 for people whose chronic graft-versus-host disease (cGVHD) affects the liver and hasn’t improved with steroids. The goal is to see if this treatment can help control the immune response without causing serious side effects.
This study tests a new medication called belumosudil to see how safe it is for people with chronic graft-versus-host disease (cGVHD). If you have had a stem cell transplant and still need treatment for cGVHD after trying other therapies, this trial may be an option.
This study tests a new medicine called belumosudil for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack the body after a stem cell transplant. The trial compares belumosudil to the best available standard treatments to see if it works better at controlling the condition.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.